David Michael Johnson
Independent DirectorMr. David Michael Johnson, also known as Dave, is Director of Incisive Genetics Inc. Mr. Johnson served as an Independent Director of Palleon Pharmaceuticals Inc. from November 2021 to 2025. He serves as Board Observer of Wugen, Inc. Mr. Johnson serves as Director of Sudo Biosciences, Inc. He served as Chairman of the Board at Zentalis Pharmaceuticals, Inc. since May 10, 2022 until November 2024. He served as Independent Director at Biosplice Therapeutics, Inc. since June 2021. He is founder and Chief Executive Officer of Solve Therapeutics since December 2021, a biologics company focused on developing novel cancer therapeutics, which he founded in January 2021 and serves as its CFO, Secretary & Director. He is Chairman of the Board at Lengo Therapeutics, Inc. (acquired by Blue Print Medicine) since May 2021. He served as Lead Independent Director at Zentalis Pharmaceuticals, Inc. since April 2020 until May 10, 2022 and serves as its Independent Director since January 2020. He has been Director at Aura Biosciences, Inc. since January 05, 2021 and also serves as Chairman of the Board since March 2021. Mr. Johnson served as Chief Executive Officer at Acerta Pharma from 2014 to March 2016 until the execution of a strategic transaction with AstraZeneca. Mr. Johnson serves as Director of Zeno Pharma, LLC. Mr. Johnson served as Chief Executive Officer of VelosBio, a position he held since co-founding the company since December 2017. Before his time as CEO at Acerta Pharma and his founding of VelosBio, Mr. Johnson held roles with increasing responsibilities within commercial, pipeline development, medical affairs and clinical development organizations at companies including Hoffman-La Roche, Immunex (acquired by Amgen), Millennium (acquired by Takeda), Favrille, Gloucester (acquired by Celgene) and Calistoga (acquired by Gilead). He served as Chairman of Oncternal Therapeutics, Inc. since May 2016. He served as a Director of Oncternal Therapeutics, Inc. He has been a Director of Presage Biosciences, Inc. since June 3, 2016. He has held roles with increasing responsibilities within Clinical Development, Medical Affairs, Pipeline Development and Commercial at companies including Calistoga (acquired by Gilead), Gloucester (acquired by Celgene), Favrille, Millennium, Immunex (acquired by Amgen) and Hoffman La Roche. He is a co-author on numerous publications including three NEJM publications. He holds a bachelor’s degree in Economics from Indiana University.
Positions
- Company NameZentalis Pharmaceuticals, Inc.Stock CodeZNTLPositionIndependent DirectorColleagues
- JMJulie M. EastlandCEO, President & Director
- SDScott D. MyersIndependent Chairman of the Board
- JBJames B. BucherChief Legal Officer & Corporate Secretary
- IBIngmar BrunsChief Medical Officer
- VAVincent A. VultaggioSVP of Finance & Principal Accounting Officer
- RJRobert J. DiVastoChief Technical Officer
- EKEnoch K. KariukiIndependent Director
- JSJan SkvarkaIndependent Director
- Company NameAura Biosciences, Inc.Stock CodeAURAPositionIndependent Chairman of the BoardColleagues
- JJJ. Jill HopkinsChief Medical Officer & President of Research and Development
- DMDavid Michael JohnsonIndependent Chairman of the Board
- NCNatalie C. HollesPresident, CEO & Director
- AEAmy ElazzouziSenior Vice President of Finance, Treasurer and Secretary
- SASusan Abu-AbsiChief Operating Officer
- ADAlex DasallaHead of Investor Relations & Corporate Communications
- GMGiovanni MariggiIndependent Director
- SSSapna SrivastavaIndependent Director
- AMAntony MattessichIndependent Director
